An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 84% of cases are classified as non–small cell lung cancer (NSCLC) (ACS, 2022). Though new screening procedures have identified more lung cancers at an earlier stage, most patients are still diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management. Chemoimmunotherapy has significantly improved the overall survival of patients compared with chemotherapy alone, but challenges remain in its optimal use (Tuminello et al, 2022). This activity will help update learners regarding this rapidly changing field. Ticiana Leal, MD, and Beth Sandy, MSN, CRNP, will analyze the latest guidance on patient selection, efficacy, safety, and supportive care strategies for non–small cell lung cancer immunotherapy.